MOS Prebiotic Potential in Older Adults | NCT05939336

Studies
MOS Prebiotic Potential in Older Adults

NCT05939336

Sponsor

University of Florida

Status

Active, not recruiting

Last Update Posted

Jan 9, 2026Actual

Enrollment

40Estimated

Phase

Not Applicable

Conditions

Healthy

Interventions

Mannooligosaccharides yeast extract

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jan 2026

Overall Recruitment Status or Expanded Access Status

Active, not recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Aug 1, 2023Actual

Primary Completion Date

Feb 28, 2024Actual

Completion Date

Jun 30, 2026Estimated

First Submitted Date

Jul 3, 2023

First Submission Date that Met QC Criteria

Jul 3, 2023

First Posted Date

Jul 11, 2023Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jan 7, 2026

Last Update Posted Date

Jan 9, 2026Actual

Name	Class
Lallemand Bio-Ingredients	OTHER

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.

Detailed Description

Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

40Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Mannooligosaccharides	Experimental	Mannooligosaccharides yeast extract	Dietary Supplement: Mannooligosaccharides yeast extract

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Mannooligosaccharides yeast extract	Dietary Supplement	15 g per day of mannooligosaccharide yeast extract.	Mannooligosaccharides

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Mean daily rating of gastrointestinal symptoms	Change from baseline mean sum of daily mean rating from 0 (no symptom) to 3 (severe symptoms)	14 days

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Adults 50-99 years of age.
Able to provide written informed consent in English.
Willingness to complete all study procedures
Healthy or diagnoses with Parkinson's or multiple system atrophy

Exclusion Criteria:

Yeast allergy.
Self-reported kidney disease.
Elite athletes or long-distance runners.
Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
Current use of laxatives or antidiarrheal medications.
Use of other investigational products within 3 months of the screening visit.
Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report).
Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection)
Current cancer treatment
Currently pregnant

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

50 Years

Maximum Age

99 Years

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Food Science and Human Nutrition Department, University of Florida		Gainesville	Florida	32611	United States

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
40117931	Derived	Moreno ML, Abbeele PVD, Baudot A, Tompkins TA, Taft DH, Yao R, Auger J, Colee J, Dahl WJ. Yeast mannans promote laxation and specifically modulate microbiota composition in older adults: An open-label pilot study. Nutr Res. 2025 Apr;136:15-27. doi: 10.1016/j.nutres.2025.02.004. Epub 2025 Feb 26.